Third Edition of Cancer Atlas highlights patterns and inequities in cancer burden

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Cancer Society, Union for International Cancer Control and International Agency for Research on Cancer have published The Cancer Atlas, 3rd edition, an overview of cancer around the globe.

The document, released at the World Cancer Leaders’ Summit in Nur-Sultan, Kazakhstan, can be downloaded here. In addition to the printed report, the information is included on this interactive website.

The atlas highlights distinct patterns and inequities in the cancer burden around the world; outlines the risk factors that are driving cancer patterns; and details the prospects for cancer prevention and control. The theme of the current edition is “Access Creates Progress.”

Cancer is the leading or second-leading cause of premature death (under age 70) in 91 countries. Based on expected population growth and aging alone, the number of global cancer cases is expected to increase by 60% in 2040. More widespread distribution of lifestyle factors such as smoking, unhealthy diet, and physical inactivity are likely to make that number considerably larger.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login